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Hypoxic Modulation of Exogenous Nitrite-Induced
Vasodilation in Humans
Abdul R. Maher, MRCP; Alexandra B. Milsom, PhD; Prasad Gunaruwan, MRCP;
Khalid Abozguia, MRCP; Ibrar Ahmed, MRCP; Rebekah A. Weaver, MSc; Philip Thomas, BMedSci;
Houman Ashrafian, MRCP; Gustav V.R. Born, PhD; Philip E. James, PhD; Michael P. Frenneaux, MD
Background—It has been proposed that under hypoxic conditions, nitrite may release nitric oxide, which causes potent
vasodilation. We hypothesized that nitrite would have a greater dilator effect in capacitance than in resistance vessels
because of lower oxygen tension and that resistance-vessel dilation should become more pronounced during hypoxemia.
The effect of intra-arterial infusion of nitrite on forearm blood flow and forearm venous volumes was assessed during
normoxia and hypoxia.
Methods and Results—Forty healthy volunteers were studied. After baseline infusion of 0.9% saline, sodium nitrite was
infused at incremental doses from 40 nmol/min to 7.84 mol/min. At each stage, forearm blood flow was measured by
strain-gauge plethysmography. Forearm venous volume was assessed by radionuclide plethysmography. Changes in
forearm blood flow and forearm venous volume in the infused arm were corrected for those in the control arm. The peak
percentage of venodilation during normoxia was 35.83.4% (meanSEM) at 7.84 mol/min (P0.001) and was
similar during hypoxia. In normoxia, arterial blood flow, assessed by the forearm blood flow ratio, increased from
1.040.09 (baseline) to 1.620.18 (nitrite; P0.05) versus 1.070.09 (baseline) to 2.370.15 (nitrite; P0.005)
during hypoxia. This result was recapitulated in vitro in vascular rings.
Conclusions—Nitrite is a potent venodilator in normoxia and hypoxia. Arteries are modestly affected in normoxia but
potently dilated in hypoxia, which suggests the important phenomenon of hypoxic augmentation of nitrite-mediated
vasodilation in vivo. The use of nitrite as a selective arterial vasodilator in ischemic territories and as a potent
venodilator in heart failure has therapeutic implications. (Circulation. 2008;117:670-677.)
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The ability of blood vessels to match oxygen delivery tometabolic demand by vasodilation in response to hypox-
ia is well described. It has been hypothesized that retrograde
propagation of vasodilating agents from capillaries or veins to
precapillary resistance vessels ensures optimal flow/demand
matching.1 The nature of the signal remains imprecisely
defined, and hypoxic vasodilation tends to persist even after
pharmacological blockade of known mediators.2 The current
consensus is that “multiple overlapping and integrated mech-
anisms or other undiscovered pathways exist, which subserve
hypoxic vasodilation.”3 Nitric oxide (NO) may be an essential
mediator of the vasodilatory response to hypoxia that may be
formed locally or transported to areas of low oxygen tension,
resulting in vasodilation.2
Editorial p 594
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Controversy surrounds the relative importance of differ-
ent endogenous NO species in mediating physiological
vasodilation. These species include nitrite, S-nitrosothiols,
N-nitrosamines, iron nitrosyls, and nitrated lipid.2 Nitrite has
traditionally been considered a weak vasodilator. In aortic
specimens, concentrations of nitrite as high as 100 to 1000
mol/L are typically required under normoxic conditions to
induce relaxation.2,4 The discrepancy between plasma nitrite
levels in vivo and the levels required to elicit a biological
effect in vitro, coupled with a study that demonstrated a lack
of vasodilator activity of 200 mol/L nitrite in the forearms
of healthy volunteers, diminished interest in nitrite.5 In
contrast, a greater focus was directed to hemoglobin acting as
an NO store, oxygen sensor, and condition-sensitive NO
donor, operating through release of the NO group from
S-nitrosohemoglobin.6
More recently, nitrite has been recognized as a powerful
signaling molecule and regulator of gene expression.7,8 Al-
though in normoxia, nitrite is a relatively inefficacious
vasodilator when acting directly, during hypoxia, this action
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may be enhanced. NO released from nitrite as a result of a
hypoxic environment may play an important physiological
role.2 Arteriovenous gradients of nitrite in the human forearm
have been observed; these gradients are enhanced during
exercise and during regional NO synthase inhibition.9,10 Thus,
it has been suggested that nitrite is consumed to liberate
bioactive NO.2,9,10 A vasoactive role for nitrite at normal
physiological concentrations is still disputed, because the
arteriovenous gradient in nitrite may result from decreased
venous nitrite production through decreased NO synthase
activity coupled with increased venous nitrite consumption.11
It has been proposed recently that deoxyhemoglobin is
capable of acting as a nitrite reductase; hence, hemoglobin
would act as an “oxygen sensor” and would liberate NO from
nitrite along the physiological oxygen gradient. The work of
Gladwin and others2 is at least hypothesis-generating with
respect to a role for nitrite in the modulation of vascular tone
in vivo.
In support of an enhanced role for nitrite in hypoxia, in
vitro nitrite administration has been shown to confer protec-
tion against ischemia/reperfusion injury in the heart, kidney,
brain, and liver.12–15 In addition, nitrite treatment has also
proved beneficial in models of hypertension,16 pulmonary
hypertension,17 and cerebral vasospasm.18
Accordingly, we hypothesized the following: (1) While
subjects were breathing room air, nitrite would be a potent
dilator of capacitance vessels in vivo because of their rela-
tively low ambient oxygen tension; (2) when subjects were
breathing 12% oxygen, which would render the resistance
vessels relatively hypoxic, nitrite would become a potent
arteriolar dilator. The present study focused on the forearm
vascular bed, the small veins and venules of which are
representative of vessels that constitute the bulk of the
capacitance bed and which behave quite differently from
conduit veins such as dorsal hand veins.19 To test the direct
effect of nitrite on vascular tissue (hemoglobin independent),
isolated rabbit vessels (aorta and vena cava) were exposed to
a range of nitrite concentrations in both normoxia and
hypoxia.
Methods
Subjects
Twenty-six healthy volunteers were recruited to protocol A and 14 to
protocol B. Subjects had no history of active smoking, hypertension,
diabetes mellitus, or hypercholesterolemia and no family history of
ischemic heart disease. None took cardioactive medication or vita-
min supplements. All had a normal cardiovascular examination and
ECG and gave written informed consent. The study was approved by
the local research ethics committee. Investigations were performed at
the University of Birmingham Clinical Research Block in a dedi-
cated vascular laboratory (22°C to 24°C), with subjects having had
a light breakfast and having abstained from caffeine-containing
drinks for at least 6 hours.
Measurement of Venous Volume
Forearm venous volume (FVV) was assessed with radionuclide
plethysmography. The details and advantages of the technique are
detailed elsewhere.20 Briefly, after the administration of stannous
fluoride, venous blood was withdrawn, radiolabeled with techne-
tium-99m, and then reinjected into the subject after 10 minutes’
incubation. After 15 minutes for stabilization, images were obtained.
A region of interest was defined, and images were obtained during
1-minute acquisition periods. At least 90% of the injected isotope
was confined to the intravascular space; therefore, forearm radioac-
tive counts were proportional to forearm blood volume. Because the
vast majority of blood in the peripheral circulation is contained
within the veins, changes in counts reflect changes in FVV.20 During
each cycle of acquisition, cuffs were inflated over both upper arms at
pressures of 0, 10, 20, and 30 mm Hg. From these data, scintigraphic
vascular volumes were plotted against cuff pressure to form a venous
pressure-volume relationship. A parallel shift of the relationship
indicated a change in venous tone.20 Data were acquired from both
the study and control arms, and any changes observed were corrected
for those that occurred in the control arm. We and others have
previously validated this technique.20–22 Importantly, we have shown
that the position of the pressure-volume relationship is not altered by
large changes in arterial inflow.19 To allow presentation of grouped
data, results were presented as percentages. The data were corrected
for physical decay of technetium.
Biochemistry
Chemicals and Reagents
Chemicals were purchased from Sigma (St Louis, Mo), other than
glacial acetic acid, high-performance liquid chromatography–grade
nitrite-free water, and hydrochloric acid, which were purchased from
Fisher Scientific (Loughborough, United Kingdom). Sodium nitrite
in the human studies was purchased from Martindale Pharmaceuti-
cals, UK (Brentwood, United Kingdom).
Ozone-Based Chemiluminescence
Plasma nitrite and protein-bound NO were measured with a triiodide
reagent linked to ozone-based chemiluminescence, as described
previously.23 The triiodide reagent is probably the most widely used
in the NO metabolite field and has been validated against standards
in several laboratories.10,24–27 The reader is referred to a complete
discussion of the assay.6,23,28–33
Stock solution of triiodide reagent was prepared fresh each
day.23,27 Immediately before analysis, frozen plasma samples were
thawed in a water bath at 37°C for 3 minutes. We have previously
shown that sample freezing has no effect on plasma NO metabolite
stability.34 The area under the curve was used in analyses, and
concentrations were calculated from a standard curve of sodium
nitrite.
Study Protocols
Protocol A (Normoxia)
Subjects were rested in a supine position. Both forearms were
positioned on the face of a gamma camera (Scintron, MiE America,
Inc, Elk Grove Village, Ill, and ADAC-Transcam, Aalborg, Den-
mark). A 20-gauge venous cannula was inserted into an antecubital
vein in each arm. Blood was drawn and sent for a full blood count
and biochemical profile. A 27-gauge arterial needle (Coopers Engi-
neering, Birmingham, United Kingdom) mounted onto a 16-gauge
epidural catheter and sealed with dental wax was then inserted into
the nondominant brachial artery under sterile conditions and kept
patent by the continuous infusion of normal saline.
Heart rate and rhythm were monitored continuously (GE Marque-
tte Dash 3000, GE Healthcare, Chalfont St Giles, United Kingdom).
Blood pressure was monitored continuously with finger plethysmog-
raphy (TNO TPD Biomedical Instrumentation, Delft, Netherlands).
Mercury-in-Silastic strain gauges were used for the measurement of
forearm blood flow (FBF; DE Hokanson, Inc, Bellevue, Wash), as
described previously.35 Changes in FBF observed in the study arm
were corrected for those that occurred in the control arm and
expressed as a ratio (FBFR; infused arm:control arm). Two venous
pressure-volume relationships were recorded, and FBF was assessed
during the infusion of normal saline. Blood was drawn from both
venous cannulas (infusion and control arm) at baseline and at each
stage of the study. Blood samples were transferred after blood gas
analysis (Bayer Rapidlab 865, Siemens, Tarrytown, NY) into 4-mL
EDTA collection tubes and were centrifuged at 2000 rpm for 10
minutes at 4°C. Plasma was snap-frozen in liquid nitrogen and stored
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at 80°C for subsequent analysis. Plasma nitrite and protein-bound
NO were measured at each stage in both protocols.
Intrabrachial nitrite infusion was then commenced at a dose of 40
nmol/min for 30 minutes. FVV was assessed at 5, 12, and 20
minutes, followed by assessment of FBF. The above was then
repeated with doses of nitrite of 100 nmol/min, 314 nmol/min, 784
nmol/min, 3.14 mol/min, and 7.84 mol/min. Left ventricular
ejection fraction was calculated by multiple-gated acquisition. In a
subset of subjects (n3), radial arterial samples were taken at
baseline and at peak nitrite infusion in which levels of nitrite and
protein-bound NO were measured.
Protocol B (Hypoxia)
Subjects were prepared as for protocol A. Oxygen saturation levels
were monitored continuously with pulse oximetry (Nellcor N-180,
Nellcor, Pleasanton, Calif). Baseline measurements of all parameters
were taken during the initial saline infusion.
Hypoxia was induced with the subject breathing 12% oxygen via
a facemask connected to a 2-way valve. When arterial oxygen
saturation levels (as measured by pulse oximetry) were stable in the
83% to 88% range (estimated pO247.5 to 55 mm Hg, based on
Severinghaus’ equation), FVV and FBF were assessed during saline
infusion (“hypoxia alone”) before the infusion of nitrite.
In 7 subjects, intrabrachial nitrite was infused at a dose of 7.84
mol/min for 20 minutes in either normoxia or hypoxia, in random
order. Saline was infused between the 2 infusions of nitrite for 60
minutes. FVV was assessed at 10 minutes into each nitrite infusion,
followed by assessment of FBF. In the remaining 7 subjects, protocol
B was performed with nitrite at a dose of 314 nmol/min to investigate
the effects of hypoxia in the context of a plasma concentration of
nitrite close to that found physiologically.
Vascular Tissue Assay
Male New Zealand White rabbits (weight 2 to 2.5 kg) were
terminally anesthetized by intravenous injection of sodium pentobar-
bital (0.75 mL/kg). The abdominal aorta and vena cava were excised
and placed in fresh Krebs buffer (NaCl 109.0 mmol/L, KCl
2.7 mmol/L, KH2PO4 1.2 mmol/L, MgSO4.7H2O 1.2 mmol/L,
NaHCO3 25.0 mmol/L, C6H12O6 11.0 mmol/L, CaCl2.2H2O
1.5 mmol/L). Vessels were cleaned and cut into 2-mm rings. Rings
were mounted on matched stainless steel hooks for isometric tension
recording in 8-mL baths containing 5 mL of Krebs buffer.
Tissue was allowed to equilibrate for 60 minutes under a resting
tension of 2g at 37°C, the buffer being exchanged every 15 minutes.
After final adjustment of the passive tension to 2g, vascular segments
were constricted with phenylephrine (1 mol/L). Once tension had
reached a plateau, acetylcholine (10 mol/L) was added to demon-
strate endothelium viability.
After extensive washout, under normoxic conditions (95% O2/5%
CO2), vessels were again constricted with 1 mol/L phenylephrine,
and sodium nitrite in Krebs buffer (10, 100, and 1000 mol/L final
concentration) was administered. Under hypoxic conditions (95%
N2/5% CO2, resulting in 1% tissue bath O2), the tissue was first
incubated for 10 minutes before exposure to 3 mol/L phenylephrine
(to achieve a similar gram tension observed at 95% O2) before
administration of sodium nitrite. Tension was recorded for a further
20 minutes with Chart for Windows (ADInstruments, Chalgrove,
United Kingdom). The minimum tension achieved was used in all
calculations. All relaxations are presented as a percentage of the
maximum tension induced by phenylephrine under the relevant
conditions.
Data and Statistical Analysis
All data are expressed as meanSEM, and probability values 0.05
were considered statistically significant. Repeated-measures analy-
ses were performed for changes in FBFR and FVV. In vitro data
were analyzed with 2-way ANOVA.
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
Subject Characteristics
Grouped baseline characteristics for all subjects are shown in
Table 1.
Protocol A: Normoxia
Venous Tone
At doses of nitrite of 784 nmol/min, 3.14 mol/min, and 7.84
mol/min, very large decreases in forearm venous tone were
observed (Figure 1). The time course over which the dilation
occurred is presented in Table 2 and Figure 2. Peak venodi-
lation (meanSEM) at 3.14 and 7.84 mol/min was 20.64.2%
(P0.05) and 35.87.5% (P0.005), respectively.
Arterial Blood Flow
Only at 3.14 and 7.84 mol/min were there noticeable
increases in FBFR (Figure 3). At baseline, FBFR was
1.00.1 (meanSEM). At 3.14 and 7.84 mol/min, FBFR
was 1.80.3 and 1.60.2, respectively (P0.05).
Plasma Nitrite and Protein-Bound NO Levels
Venous plasma nitrite levels were significantly greater in the
infused versus control arm at doses of 314 nmol/mL
Table 1. Grouped Baseline Characteristics for All Subjects
Demographic and Clinical Features
Age, y 56.51.4
Sex, M/F, n 27/6
Body mass index, kg/m2 27.00.6
Smoking history, n
Nonsmoker 32
Previous smoker 1
Current smoker 0
Serum cholesterol, mmol/L 5.60.2
Plasma glucose, mmol/L 4.80.1
Serum creatinine, mol/L 99.63.1
Heart rate, bpm 64.02.0
Blood pressure, mm Hg
Systolic 1292.2
Diastolic 73.11.7
Left ventricular ejection fraction, % 58.32.7
Continuous data are presented as meanSEM.
Figure 1. Change in peak FVV under normoxic conditions. Data
are expressed as percentage change from baseline (saline infu-
sion). All values are presented as meanSEM. *P0.05 and
***P0.001 vs saline infusion.
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(P0.05; Figure 4. No statistically significant differences
were present in venous levels of plasma protein-bound NO
between the 2 arms at any dose Figure 4).
Arterial levels of plasma protein-bound NO in the infused
arm increased from 64.05.8 nmol/L at baseline to
83.823.8 nmol/L (Figure 5B; PNS).
Protocol B: Hypoxia
Venous Tone and FBF
Venodilation was similar between normoxia and hypoxia;
however, hypoxia significantly enhanced the increase in
FBFR during nitrite infusion. The mean increase in FBFR
during high-dose nitrite infusion (7.84 mol/min) in hypoxia
was significantly greater than that in normoxia (P0.05;
Figure 6). Low-dose nitrite (314 nmol/min) had little effect
during normoxia but increased FBFR during hypoxia
(P0.05; Figure 7).
In Vitro Work
Nitrite-induced vessel relaxation increased proportionally
with increasing nitrite concentrations in both the aorta and the
vena cava (P0.05; Figure 8). No statistical difference was
observed between the degree of nitrite-induced relaxation in
the aorta versus vena cava under normoxia. Hypoxia en-
hanced nitrite-induced relaxation in both vessel types com-
pared with relaxation under normoxia; however, veins had a
proportionally greater relaxation than arteries at 100 and 1000
mol/L nitrite (P0.01).
Discussion
The present study showed that under normoxic conditions,
exogenous nitrite-induced vasodilation in humans occurred
predominantly in capacitance vessels. Under these condi-
tions, nitrite only modestly increased FBF (1.6), even at
maximal arterial nitrite concentrations (30 mol/L). Al-
though hypoxia had no incremental influence on the effects of
nitrite on capacitance vessels, at similar concentrations (55
mol/L), it had a profound relaxing effect on resistance
vessels. The in vitro studies confirmed this influence of
hypoxia on nitrite-induced relaxation in both arteries and
veins, which suggests that oxygen tension is a major deter-
minant of the degree of response to nitrite.
Until recently, the nitrite anion was regarded as a relatively
inert byproduct of NO metabolism and even as a potentially
carcinogenic source of N-nitroso compounds.36 Recently,
research has shown nitrite to be a distinct and important
signaling molecule.8 Normoxic studies with animal aortic
strips appeared to preclude a physiological role,4 but in
contradistinction, a physiological function for nitrite has been
supported by the capacity of physiological nitrite concentra-
tions (1 to 2 mol/L) to dilate human resistance vessels.9
We have now shown that exogenous nitrite is a potent
dilator of the venous capacitance bed in humans under both
normoxic and hypoxic conditions. At the peak dose, we
observed 40% venodilation; this is a large effect. Because
up to 70% of the circulating blood volume resides within the
capacitance bed, even subtle modifications of venous tone
Figure 3. FBF at incremental doses of sodium nitrite under nor-
moxic conditions. Data are expressed as a ratio of infused arm
to control arm (FBF-R) to correct for any systemic changes. Val-
ues are meanSEM. *P0.05.
Figure 4. Plasma nitrite (A) and protein-bound NO (B) levels
under normoxic conditions. All values are presented as
meanSEM. *P0.05 and ***P0.001 vs control arm.
Table 2. Venodilation at Doses of Sodium Nitrite at 5, 12, and
20 Minutes of Infusion
% Venodilation
Dose of Nitrite 5 min 12 min 20 min
40 nmol/min 2.21.7 2.82.7 4.21.5
100 nmol/min 5.12.6 3.12.3 0.84.6
314 nmol/min 1.63.1 8.24.0 8.14.3
784 nmol/min 4.02.5 7.32.7 10.32.8
3.14 mol/min 17.64.1 19.13.3* 20.64.2*
7.84 mol/min 29.110.1† 30.74.3‡ 35.87.5‡
All values are presented as meanSEM.
*P0.05, †P0.005, and ‡P0.001 vs baseline.
Figure 2. Venodilation measured at 5, 12, and 20 minutes dur-
ing infusion of nitrite at each of the infusion doses during
normoxia.
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can result in large changes in central blood volume and
cardiac “preload.” Accordingly, a strong selective venodilator
may confer distinct benefits in the treatment of heart failure.
We have previously used carbachol extensively in studies
assessing venous capacitance.37 At its peak dose, a maximal
3- to 4-fold increase in FBF and a 40% venodilation was
observed.19 Thus, nitrite exerts venodilatory effects similar to
those of carbachol with comparatively modest effects on
resistance vessels during normoxia.
The enhanced resistance-vessel response to nitrite during
hypoxia is consistent with the findings of Cosby et al,9 who
observed that the vasodilatory effects of intra-arterial nitrite
were enhanced by the tissue hypoxia induced by exercise of
the forearm. Moreover, the present study answers many of the
questions that were raised after publication of the study by
Cosby et al9 and demonstrates in particular that hypoxia per
se is a primary determinant in the action of nitrite. We found
that in normoxia, low-dose nitrite (314 nmol/min) had no
discernable effect on FBF, whereas Cosby et al9 observed a
29% increase in FBF in response to nitrite infused at 400
nmol/min in normoxia, but Lauer et al5 reported that exoge-
nous nitrite had no effect at all on FBF, even at doses as high
as 36 mol/min. The reasons for this discrepancy may pertain
to differences in the subjects and the experimental protocols,
although such differences are not obvious because the prep-
aration of nitrite and its infusion were similar. It is unlikely
that subjects in the present study differed significantly in
sympathetic stimulation.38 It is possible, however, that het-
erogeneity exists in the handling of nitrite. In the present
study, we found a significant degree of variation in the
responses observed. Although in the majority of individuals,
nitrite doses as low as 314 nmol/min had little measurable
effect on FBFR, in a few subjects, the effect was more
pronounced. In 1 individual, the FBFR increased by 27%.
Such heterogeneity may explain some of the apparently
contradictory findings in the literature and provides an
interesting avenue for future work.
Although in normoxia, nitrite was a weak vasodilator of
resistance vessels compared with agents such as acetylcho-
line39 and bradykinin40 that can induce a 3- to 4-fold increase
Figure 5. Arterial levels of plasma nitrite in the infused arm
increased from 23327.0 nmol/L at baseline to 34.112.3
mol/L (Figure 5A; P0.05).
Figure 6. Effect of hypoxia on venodilation (A) and FBFR (B)
induced by intrabrachial nitrite (7.84 mol · L1 · min1). Values
are meanSEM. *P0.05 vs baseline; #P0.05 vs normoxia
and nitrite.
Figure 7. Effect of hypoxia on venodilation (A) and FBFR (B)
induced by intrabrachial nitrite (314 nmol · L1 · min1). Values
are meanSEM. *P0.05 vs normoxia and nitrite.
Figure 8. Relaxation of aorta and inferior vena cava after 20
minutes of incubation with varying nitrite concentrations under
either normoxic or hypoxic conditions. Data are meanSEM.
Each data set is n4 to 5.
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in FBF, in hypoxia, we show that it becomes an arterial
vasodilator of comparable potency to these agents. Impor-
tantly, a significant augmentation in FBFR during hypoxia
was also seen with low-dose (314 nmol/min) nitrite, which
implies a possible physiological role under hypoxic
conditions.
Our vascular ring studies confirmed that in the absence of
hemoglobin, nitrite-induced dilatation of veins and arteries is
more profound in the context of hypoxia than in normoxia,
which confirms the present findings in vivo. In vitro, during
hypoxia, relaxation of veins was greater than that of arteries;
however, it is not valid to directly compare potency between
arteries and veins and extrapolate to the in vivo situation
because of the nonphysiological nature of the preparation,
which measures relaxation from a preconstricted state rather
than changes in basal tone.
Although the present study confirms a role for hypoxia in
facilitating exogenous nitrite-induced vasodilation, no con-
clusion can be drawn about the mechanisms subserving this
effect. Both nonenzymatic chemical reactions41 and nitrite
reductase species42 as diverse as hemoglobin,9,30,43 xanthine
oxidase,15 and endothelial NO synthase,44 as well as the
mitochondrial enzymes cytochrome c oxidase and the bc1
complex,45 reduce nitrite hypoxically in vitro; however, their
relative contribution to the hypoxic vasodilatory response in
vivo remains unresolved.2,11,42 In subjects infused with nitrite,
NO adducts of hemoglobin are increased, and it has been
suggested that hemoglobin is a key nitrite reductase.9 Hemo-
globin can subserve a number of roles, including nitrite
reductase in hypoxia; as an acceptor of the resulting NO
(eg, through HbNO); and as a donor of NO precisely where
it is required, ie, at the site of hypoxia (through
S-nitrosohemoglobin). These multiple personalities make he-
moglobin an attractive nitrite modulator. A recent in vitro
study46 has observed that nitrite-dependent vasodilation con-
forms to first-order reaction kinetics with respect to nitrite
concentration. Using selective inhibitors during hypoxia, that
study indicated that nitrite-induced vasorelaxation was inde-
pendent of the nitrite reductases listed above and importantly
was inhibited by oxygenated hemoglobin but not by deoxy-
genated hemoglobin.46 The study did not exclude a role for
hemoglobin as a nitrite modulator in vivo. If nitrite is subject
to hemoglobin-mediated NO production, how the resulting
products or NO itself escapes from the red blood cell is not
yet clear, because such an escape is difficult to reconcile with
the diffusional limitations and the time constraints of an
extremely quick A-to-V transit time.11
To reconcile the site and mechanism of action of nitrite in
vivo, vascular preparations will need to be investigated
further. Specific agents and inhibitors are required to identify
putative nitrite reductases, eg, hemoglobin, myoglobin, neu-
roglobin, and other heme proteins, such as hypoxia-
dependent nitrite reductases.47 The species to which nitrite is
converted and which activate guanylate cyclase, eg, NO, iron
nitrosyl, N-nitroso, and S-nitroso complexes, will also need to
be identified. Parallel in vivo studies will supplement the in
vitro studies. In the present study, venous plasma nitrosothiol
levels rose similarly in both arms, which suggests that
protein-bound NO in the plasma compartment did not medi-
ate the venous dilation directly. This, however, does not
preclude protein-bound NO within the red blood cells or
within the vascular compartment contributing to the bioactive
effects of nitrite.
Study Limitations
The present study was performed in healthy volunteers, and
the response to nitrite may differ in disease. In addition,
organ-chamber bioassays are limited by the complicating
factor of varying baseline tension in precontracted vessels.11
Because different vessels (capacitance versus resistance)
show different and nonlinear responses, such bioassay results
should be assessed judiciously, and any interpretation of
apparent differences between vessel types should be guarded.
Nonetheless, the present in vivo and in vitro studies are
consistent internally. Finally, the present results increase the
understanding of the synergy between nitrite and hypoxia but
provide limited insights into the role of endogenous nitrites in
physiology. We speculate that the present study may also
implicate a role for endogenous nitrites in hypoxic vessels,
but we have limited any discussion of the role of nitrite in
physiological hypoxic vasodilatation.11 Even in the in vitro
assays, in which unphysiologically high concentrations of
nitrite (100 mol/L) have been required previously, careful
attention to precontraction and incipient conditions reveals
that physiological concentrations of nitrite (0.1 to 10 mol/L)
can modulate tone.46
Conclusions
The present study confirms that hypoxia per se is a prime
determinant of the in vivo response to exogenous nitrite. Both
capacitance and resistance vessels respond profoundly to
relatively modest pharmacological concentrations of exoge-
nous nitrite in hypoxia. Although for some years, it has been
speculated on the basis of studies in normoxic and exercising
patients that “therapeutic application of nitrite should result in
selective vasodilation to hypoxemic tissue, and could be used
to treat diseases associated with ischemia,”9 the present study
confirms the role for nitrite in resistance-vessel dilatation in
human hypoxic tissues. Corresponding therapeutic implica-
tions exist in conditions such as heart failure, in which
selective venodilation would reduce intracardiac pressure in
the absence of resistance-vessel dilatation, thus avoiding
hypotension. Perhaps more importantly, pharmacological
doses of nitrite may constitute a specific hypoxically bioac-
tive agent that targets only hypoxic vessels.12,48,49 A prelim-
inary indication of the importance of nitrite has been afforded
by data presented by Arai,2 who demonstrated that a brief
nitrite infusion (plasma concentration of 5 mol/L) de-
creased myocardial infarction size from 70% to 20%. In
addition to confirming the present findings, future studies will
have to assess the therapeutic role of nitrite in disease.
Acknowledgments
Special thanks to Bill Thomson, Joe O’Brien, and the radiopharmacy
team for their medical physics and radiopharmaceutical support. We
also acknowledge Janis Weeks (Medical Microbiology, Cardiff) for
conducting the plasma nitrite/protein NO measurements and for her
expertise in the biochemical aspects of this study.
Maher et al Hypoxic Modulation of Nitrite-Induced Vasodilation 675
 at Cardiff University on February 19, 2014http://circ.ahajournals.org/Downloaded from 
Sources of Funding
This research was supported by the British Heart Foundation.
Disclosures
Dr Frenneaux has received a research grant from Medtronic. He has
an ownership interest in a “method of use” patent held for Perhexi-
line in Chronic Heart Failure. He has also served on the advisory
board or as a consultant to Medtronic and Biotronic and has received
sponsorship from Medtronic, Biotronic, Servier, Novartis, and AstraZeneca
to attend meetings.
References
1. Segal SS, Duling BR. Flow control among microvessels coordinated by
intercellular conduction. Science. 1986;234:868–870.
2. Arai A. Low-dose nitrite ameliorates myocardial ischemia/reperfusion
injury and reduces infarct size in a canine model. Presented at: Role of
Nitrite in Physiology, Pathophysiology, and Therapeutics Meeting; Sep-
tember 8–9, 2005; Bethesda, Md. Cited by Gladwin MT, Raat NJ, Shiva
S, Dezfulian C, Hogg N, Kim-Shapiro DB, Patel RP. Nitrite as a vascular
endocrine nitric oxide reservoir that contributes to hypoxic signaling,
cytoprotection, and vasodilation. Am J Physiol Heart Circ Physiol. 2006;
291:H2026–H2035.
3. Segal SS. Regulation of blood flow in the microcirculation. Microcirculation.
2005;12:33–45.
4. Furchgott RF, Bhadrakom S. Reactions of strips of rabbit aorta to epi-
nephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol
Exp Ther. 1953;108:129–143.
5. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, Kelm M.
Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide
synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci
U S A. 2001;98:12814–12819.
6. Singel DJ, Stamler JS. Chemical physiology of blood flow regulation by
red blood cells: the role of nitric oxide and S-nitrosohemoglobin. Annu
Rev Physiol. 2005;67:99–145.
7. Bryan NS, Fernandez BO, Bauer SM, Garcia-Saura MF, Milsom AB,
Rassaf T, Maloney RE, Bharti A, Rodriguez J, Feelisch M. Nitrite is a
signaling molecule and regulator of gene expression in mammalian
tissues. Nat Chem Biol. 2005;1:290–297.
8. Bryan NS. Nitrite in nitric oxide biology: cause or consequence? A
systems-based review. Free Radic Biol Med. 2006;41:691–701.
9. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang
BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro
DB, Schechter AN, Cannon RO III, Gladwin MT. Nitrite reduction to
nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat
Med. 2003;9:1498–1505.
10. Gladwin MT, Shelhamer JH, Schechter AN, Pease-Fye ME, Waclawiw
MA, Panza JA, Ognibene FP, Cannon RO III. Role of circulating nitrite
and S-nitrosohemoglobin in the regulation of regional blood flow in
humans. Proc Natl Acad Sci U S A. 2000;97:11482–11487.
11. Luchsinger BP, Rich EN, Yan Y, Williams EM, Stamler JS, Singel DJ.
Assessments of the chemistry and vasodilatory activity of nitrite with
hemoglobin under physiologically relevant conditions. J Inorg Biochem.
2005;99:912–921.
12. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W,
Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ. Cytopro-
tective effects of nitrite during in vivo ischemia-reperfusion of the heart
and liver. J Clin Invest. 2005;115:1232–1240.
13. Jung KH, Chu K, Ko SY, Lee ST, Sinn DI, Park DK, Kim JM, Song EC,
Kim M, Roh JK. Early intravenous infusion of sodium nitrite protects
brain against in vivo ischemia-reperfusion injury. Stroke. 2006;37:
2744–2750.
14. Tripatara P, Patel NS, Webb A, Rathod K, Lecomte FM, Mazzon E,
Cuzzocrea S, Yaqoob MM, Ahluwalia A, Thiemermann C. Nitrite-
derived nitric oxide protects the rat kidney against ischemia/reperfusion
injury in vivo: role for xanthine oxidoreductase. J Am Soc Nephrol.
2007;18:570–580.
15. Webb A, Bond R, McLean P, Uppal R, Benjamin N, Ahluwalia A.
Reduction of nitrite to nitric oxide during ischemia protects against
myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A.
2004;101:13683–13688.
16. Beier S, Classen HG, Loeffler K, Schumacher E, Thoni H. Antihyper-
tensive effect of oral nitrite uptake in the spontaneously hypertensive rat.
Arzneimittelforschung. 1995;45:258–261.
17. Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous
nitrite improves hemodynamics in a canine model of acute pulmonary
thromboembolism. Free Radic Biol Med. 2006;41:1764–1770.
18. Pluta RM, Dejam A, Grimes G, Gladwin MT, Oldfield EH. Nitrite
infusions to prevent delayed cerebral vasospasm in a primate model of
subarachnoid hemorrhage. JAMA. 2005;293:1477–1484.
19. Blackman DJ, Morris-Thurgood JA, Atherton JJ, Ellis GR, Anderson RA,
Cockcroft JR, Frenneaux MP. Endothelium-derived nitric oxide contributes
to the regulation of venous tone in humans. Circulation. 2000;101:165–170.
20. Schmitt M, Blackman DJ, Middleton GW, Cockcroft JR, Frenneaux MP.
Assessment of venous capacitance: radionuclide plethysmography: meth-
odology and research applications. Br J Clin Pharmacol. 2002;54:565–576.
21. Clements IP, Strelow DA, Becker GP, Vlietstra RE, Brown ML. Radio-
nuclide evaluation of peripheral circulatory dynamics: new clinical appli-
cation of blood pool scintigraphy for measuring limb venous volume,
capacity, and blood flow. Am Heart J. 1981;102:980–983.
22. Manyari DE, Malkinson TJ, Robinson V, Smith ER, Cooper KE. Acute
changes in forearm venous volume and tone using radionuclide plethys-
mography. Am J Physiol. 1988;255:H947–H952.
23. Rogers SC, Khalatbari A, Gapper PW, Frenneaux MP, James PE.
Detection of human red blood cell-bound nitric oxide. J Biol Chem.
2005;280:26720–26728.
24. Feelisch M, Rassaf T, Mnaimneh S, Singh N, Bryan NS, Jourd’Heuil D,
Kelm M. Concomitant S-, N-, and heme-nitros(yl)ation in biological
tissues and fluids: implications for the fate of NO in vivo. FASEB J.
2002;16:1775–1785.
25. Rassaf T, Preik M, Kleinbongard P, Lauer T, Heiss C, Strauer BE,
Feelisch M, Kelm M. Evidence for in vivo transport of bioactive nitric
oxide in human plasma. J Clin Invest. 2002;109:1241–1248.
26. Xu X, Cho M, Spencer NY, Patel N, Huang Z, Shields H, King SB,
Gladwin MT, Hogg N, Kim-Shapiro DB. Measurements of nitric oxide on
the heme iron and beta-93 thiol of human hemoglobin during cycles of
oxygenation and deoxygenation. Proc Natl Acad Sci U S A. 2003;100:
11303–11308.
27. Yang BK, Vivas EX, Reiter CD, Gladwin MT. Methodologies for the
sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and
nitrite in biological samples. Free Radic Res. 2003;37:1–10.
28. Hausladen A, Rafikov R, Angelo M, Singel DJ, Nudler E, Stamler JS.
Assessment of nitric oxide signals by triiodide chemiluminescence. Proc
Natl Acad Sci U S A. 2007;104:2157–2162.
29. MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite
and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B
Analyt Technol Biomed Life Sci. 2007;851:93–105.
30. Nagababu E, Ramasamy S, Abernethy DR, Rifkind JM. Active nitric
oxide produced in the red cell under hypoxic conditions by
deoxyhemoglobin-mediated nitrite reduction. J Biol Chem. 2003;278:
46349–46356.
31. Rassaf T, Bryan NS, Maloney RE, Specian V, Kelm M, Kalyanaraman B,
Rodriguez J, Feelisch M. NO adducts in mammalian red blood cells: too
much or too little? Nat Med. 2003;9:481–482.
32. Stamler JS. S-nitrosothiols in the blood: roles, amounts, and methods of
analysis. Circ Res. 2004;94:414–417.
33. Wang X, Bryan NS, MacArthur PH, Rodriguez J, Gladwin MT, Feelisch
M. Measurement of nitric oxide levels in the red cell: validation of
tri-iodide-based chemiluminescence with acid-sulfanilamide pre-
treatment. J Biol Chem. 2006;281:26994–27002.
34. Rogers SC, Khalatbari A, Datta BN, Ellery S, Paul V, Frenneaux MP,
James PE. NO metabolite flux across the human coronary circulation.
Cardiovasc Res. 2007;75:434–441.
35. Gunaruwan P, Schmitt M, Taylor J, Lee L, Struthers A, Frenneaux M.
Lack of rapid aldosterone effects on forearm resistance vasculature in
health. J Renin Angiotensin Aldosterone Syst. 2002;3:123–125.
36. Gladwin MT. Nitrite as an intrinsic signaling molecule. Nat Chem Biol.
2005;1:245–246.
37. Nightingale AK, Blackman DJ, Ellis GR, Schmitt M, Morris-Thurgood
JA, Jones EA, Frenneaux MP. Preservation of venous endothelial
function in the forearm venous capacitance bed of patients with chronic
heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol.
2001;37:1062–1068.
38. Weisbrod CJ, Minson CT, Joyner MJ, Halliwill JR. Effects of regional
phentolamine on hypoxic vasodilatation in healthy humans. J Physiol.
2001;537:613–621.
39. Larrousse M, Bragulat E, Segarra M, Sierra C, Coca A, de La Sierra A.
Increased levels of atherosclerosis markers in salt-sensitive hypertension.
Am J Hypertens. 2006;19:87–93.
676 Circulation February 5, 2008
 at Cardiff University on February 19, 2014http://circ.ahajournals.org/Downloaded from 
40. Wotherspoon F, Browne DL, Meeking DR, Allard SE, Munday LJ, Shaw
KM, Cummings MH. The contribution of nitric oxide and vasodilatory
prostanoids to bradykinin-mediated vasodilation in type 1 diabetes.
Diabet Med. 2005;22:697–702.
41. Zweier JL, Wang P, Samouilov A, Kuppusamy P. Enzyme-independent
formation of nitric oxide in biological tissues. Nat Med. 1995;1:804–809.
42. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in
vascular control. Arterioscler Thromb Vasc Biol. 2005;25:915–922.
43. Doyle MP, Pickering RA, DeWeert TM, Hoekstra JW, Pater D. Kinetics
and mechanism of the oxidation of human deoxyhemoglobin by nitrites.
J Biol Chem. 1981;256:12393–12398.
44. Gautier C, van Faassen E, Mikula I, Martasek P, Slama-Schwok A.
Endothelial nitric oxide synthase reduces nitrite anions to NO under
anoxia. Biochem Biophys Res Commun. 2006;341:816–821.
45. Kozlov AV, Staniek K, Nohl H. Nitrite reductase activity is a novel
function of mammalian mitochondria. FEBS Lett. 1999;454:127–130.
46. Dalsgaard T, Simonsen U, Fago A. Nitrite-dependent vasodilation is
facilitated by hypoxia and is independent of known NO-generating nitrite
reductase activities. Am J Physiol Heart Circ Physiol. 2007;292:
H3072–H3078.
47. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE,
Huang KT, Ho C, Hogg N, Schechter AN, Gladwin MT. Enzymatic
function of hemoglobin as a nitrite reductase that produces NO under
allosteric control. J Clin Invest. 2005;115:2099–2107.
48. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions
of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics.
Arterioscler Thromb Vasc Biol. 2006;26:697–705.
49. Lefer DJ. Nitrite therapy for protection against ischemia-reperfusion
injury. Am J Physiol Renal Physiol. 2006;290:F777–F778.
CLINICAL PERSPECTIVE
Advances in cardiovascular treatment could be made through the understanding and utilization of nitrite as a stable store
of transported nitric oxide, allowing the targeted delivery of nitric oxide precisely where it is needed, both physiologically
and therapeutically. Data are presented that demonstrate that nitrite-induced vasodilation in humans is a function of ambient
oxygen tension. Subjects received intrabrachial sodium nitrite while breathing either room air or 12% oxygen. During
normoxia, the nitrite infusion had modest effects in resistance vessels but caused a significant vasodilation in the relatively
hypoxic capacitance bed. However, when the oxygen tension in the resistance vessels decreased because the subjects were
breathing 12% oxygen, nitrite caused a marked dilatation in this bed. Nitrite has been shown to decrease infarct size by
up to 50% in a canine model of myocardial infarction. Studies are under way to ascertain whether nitrite is as potent in
reducing myocardial damage in humans. Similarly, nitrite has been shown to mitigate ischemia-reperfusion injury of the
brain, kidney, and liver. The present findings suggest that nitrite may play a role in the physiological defense against
ischemia. This mechanism lends itself to therapeutic exploitation in clinical scenarios such as acute coronary syndromes
in which critical ischemia is the primary underlying pathology. This mechanism potentially may also be used in the
treatment of acute decompensated heart failure. The use of a selective venodilator could avoid the deleterious hypotensive
effects of current vasodilators that cause a significant degree of arterial vasodilation.
Maher et al Hypoxic Modulation of Nitrite-Induced Vasodilation 677
 at Cardiff University on February 19, 2014http://circ.ahajournals.org/Downloaded from 
